425: Aerovate Therapeutics and Jade Biosciences Announce Merger Agreement, Creating Autoimmune Disease Focused Company

Aerovate Therapeutics and Jade Biosciences have announced a merger agreement to create a company focused on advancing Jade Biosciences' portfolio of novel therapies for autoimmune diseases.

Summary

• Aerovate Therapeutics and Jade Biosciences have entered into a definitive merger agreement for an all-stock transaction.
• The resulting entity will focus on advancing Jade's portfolio of novel biologics, including JADE-001, an anti-APRIL monoclonal antibody (mAb) for IgA nephropathy (IgAN).
• Upon completion of the merger, the combined company plans to operate under the name Jade Biosciences and trade on Nasdaq under the ticker symbol JBIO.
• Jade has secured commitments for an oversubscribed private investment that is expected to result in total gross proceeds of approximately $300 million.
• The financing includes common stock and pre-funded warrants to purchase additional shares of common stock and reflects the conversion of the previously issued $95 million convertible notes.
• The financing is expected to close immediately prior to completion of the merger, with the combined company's cash balance at closing anticipated to fund Jade's operations through 2027 and advance JADE-001 to initial clinical proof-of-concept.
• Prior to closing, Aerovate expects to declare a cash dividend to pre-merger Aerovate stockholders, distributing excess net cash expected to be approximately $65 million.
• Pre-merger Aerovate stockholders are expected to own approximately 1.6% of the combined company, while pre-merger Jade stockholders are expected to own approximately 98.4% of the combined entity.
• The transaction has received approval by the Boards of Directors of both companies and is expected to close in the first half of 2025, subject to customary closing conditions.
• The combined company will be led by Tom Frohlich, Jade's current CEO, and Jades existing Board of Directors will remain in place, chaired by Eric Dobmeier.

Sentiment

Score: 8

Explanation: The document is generally positive, highlighting the potential of the merger and the financial backing secured by Jade Biosciences. The forward-looking statements are tempered with cautionary language, but the overall tone is optimistic.

Positives

• The merger creates a company focused on developing therapies for autoimmune diseases, an area of significant unmet need.
• Jade Biosciences has secured substantial funding to advance its pipeline through clinical development.
• JADE-001 has a potential best-in-class profile with superior potency and an extended half-life, optimizing efficacy with convenient, infrequent dosing.
• The combined company is expected to have sufficient cash to fund operations through 2027.
• The merger is expected to provide Aerovate stockholders with a compelling opportunity for significant value creation.

Negatives

• Pre-merger Aerovate stockholders are expected to own a small percentage (approximately 1.6%) of the combined company.
• The merger is subject to customary closing conditions, including stockholder approval, which could delay or prevent the transaction from closing.

Risks

• The success of Jade Biosciences' pipeline is subject to the risks and uncertainties inherent in drug development, including clinical trial results and regulatory approvals.
• The combined company's ability to remain listed on Nasdaq is subject to certain requirements and could be impacted by various factors.
• The combined company's cash resources could be reduced by unanticipated spending and costs.
• The merger may face competitive responses and potential adverse reactions or changes to business relationships.

Future Outlook

The combined company will focus on advancing Jade's pipeline of novel biologics, with JADE-001 expected to enter the clinic in the second half of 2025 and initial data expected in the first half of 2026.

Management Comments

• Tom Frohlich, CEO of Jade, stated that the merger and strong financial backing position the company well to advance its programs into clinical development and make meaningful progress in treating autoimmune diseases.
• Tim Noyes, CEO of Aerovate, stated that the merger with Jade represents the best path forward for Aerovate stockholders and offers a compelling opportunity for significant value creation.

Industry Context

The announcement reflects a trend of mergers and acquisitions in the biotechnology industry, particularly in the autoimmune disease space, as companies seek to expand their pipelines and leverage synergies.

Comparison to Industry Standards

• Jade Biosciences is the fourth company founded on assets licensed from Paragon Therapeutics, following in the footsteps of Apogee, Spyre, and Oruka, which have collectively raised ~$1.8B.
• JADE-001 is engineered to deliver superior potency and an extended half-life compared to other anti-APRIL monoclonal antibodies in development, such as sibeprenlimab and zigakibart.
• The proposed updates to KDIGO guidelines highlight the need for therapies like JADE-001, which may reduce pathogenic IgA.
• The company is targeting a clinical remission definition of <0.3g/day urinary protein excretion, which is highly used in the sibeprenlimab Phase 2.

Management Changes

Stakeholder Impact

• Aerovate stockholders are expected to receive a cash dividend and own a portion of the combined company.
• Jade stockholders are expected to own a majority of the combined company and benefit from the increased resources and public listing.
• Patients with autoimmune diseases may benefit from the development of new therapies.
• Employees of both companies may be affected by the integration of the two organizations.

Next Steps

• Obtain stockholder approval from both Aerovate and Jade.
• File a registration statement with the SEC.
• Close the pre-closing financing.
• Complete the merger in the first half of 2025.
• Initiate a clinical trial for JADE-001 in the second half of 2025.

Key Dates